semaglutide and ipamorelin – Princeton Peptides (ARL) The goal isn't weight loss.

What this means for you Weight-loss drugs are almost always excluded on individual plans

doi: 10.1001/jamaoncol.2023.5573

One reason these peptides are often discussed together is their complementary action : BPC-157 : May work in more localized areas, such as injured tendons or inflamed joints, by supporting blood flow and tissue repair

People know it due to its growth-stimulating effects on bones and cartilage

Major medical organizations, including the American Diabetes Association and the Obesity Society, recognize GLP-1 therapy as an ongoing treatment for weight maintenance, not a short-term intervention

The addition of glucagon receptor agonism introduces some theoretical safety considerations not seen with GLP-1 agonists alone